Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease

Contributed by: Business Wire

Logo

Tags

Biotechnology

Technology

FDA

Health

Pharmaceutical

Health Technology

Research

Nanotechnology

Genetics

Science

Clinical Trials

IN013

More Like This

PR Newswire associated0

U.S. FDA AWARDS BOTH RARE PEDIATRIC DISEASE AND ORPHAN DRUG DESIGNATIONS TO HG204, A CRISPR RNA-EDITING THERAPY, FOR THE TREATMENT OF MECP2 DUPLICATION SYNDROME

Oranda Therapeutics Announces Series A Funding Round to support its mission: to improve the lives of patients living with rare disease

ReNAgade Therapeutics to Present Preclinical Data Demonstrating Potent Extra-Hepatic Delivery of mRNA Using Proprietary Lipid Nanoparticles at 11th International mRNA Health Conference

BioArctic receives Orphan Drug Designation for exidavnemab the US

PR Newswire associated0

Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in Europe to Treat Idiopathic Pulmonary Fibrosis

PR Newswire associated0

Orphalan becomes the first European company to enter in China's Wilson Disease market

PR Newswire associated0

HUIDAGENE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN MULTINATIONAL PHASE 1/2 TRIAL OF HG004 FOR INHERITED BLINDNESS

Neuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset